688578 艾力斯
已收盘 11-04 15:00:00
资讯
新帖
简况
艾力斯Q3收入增速放缓，核心产品增量市场遭竞品冲击
时代周报 · 11-01
艾力斯Q3收入增速放缓，核心产品增量市场遭竞品冲击
中原证券：给予艾力斯买入评级
证券之星 · 11-01
中原证券：给予艾力斯买入评级
阿斯利康骗保案余波未了：中国区“一把手”王磊配合调查 重磅肺癌药面临国产药“围剿”
ÿվ · 11-01
阿斯利康骗保案余波未了：中国区“一把手”王磊配合调查 重磅肺癌药面临国产药“围剿”
中原证券给予艾力斯买入评级，季报点评：“内生+外延”双轮驱动业绩增长
每日经济新闻 · 11-01
中原证券给予艾力斯买入评级，季报点评：“内生+外延”双轮驱动业绩增长
艾力斯11月01日遭主力抛售1425万元 环比增加193.81%
市场透视 · 11-01
艾力斯11月01日遭主力抛售1425万元 环比增加193.81%
【机构调研记录】蜂巢基金调研特宝生物、艾力斯
证券之星 · 10-30
【机构调研记录】蜂巢基金调研特宝生物、艾力斯
【机构调研记录】英大基金调研艾力斯、华测检测
证券之星 · 10-30
【机构调研记录】英大基金调研艾力斯、华测检测
【机构调研记录】汇安基金调研苑东生物、艾力斯等3只个股（附名单）
证券之星 · 10-30
【机构调研记录】汇安基金调研苑东生物、艾力斯等3只个股（附名单）
10月29日艾力斯发布公告，其股东减持450万股
证券之星 · 10-29
10月29日艾力斯发布公告，其股东减持450万股
艾力斯10月29日现7笔大宗交易 成交金额4345.01万元
新浪证券-红岸工作室 · 10-29
艾力斯10月29日现7笔大宗交易 成交金额4345.01万元
10月29日艾力斯现7笔大宗交易 机构净买入750万元
证券之星 · 10-29
10月29日艾力斯现7笔大宗交易 机构净买入750万元
艾力斯：伏美替尼持续快速放量、对外合作储备未来管线
招商证券 · 10-27
艾力斯：伏美替尼持续快速放量、对外合作储备未来管线
艾力斯（688578）10月25日主力资金净卖出39.29万元
证券之星 · 10-26
艾力斯（688578）10月25日主力资金净卖出39.29万元
艾力斯（688578）2024年三季报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 10-26
艾力斯（688578）2024年三季报简析：营收净利润同比双双增长，应收账款上升
艾力斯10月25日主力资金流入332万元 连续3日加仓
市场透视 · 10-25
艾力斯10月25日主力资金流入332万元 连续3日加仓
艾力斯大跌5.02% 2家券商给予增持建议
智选洞察 · 10-25
艾力斯大跌5.02% 2家券商给予增持建议
艾力斯(688578.SH)发前三季业绩，净利润10.63亿元，同比增长158.99%
智通财经 · 10-24
艾力斯(688578.SH)发前三季业绩，净利润10.63亿元，同比增长158.99%
公司热点｜复星医药向艾力斯索赔2.55亿元：昔日合作伙伴各执一词 “药物推广”纠纷升级
读创财经 · 10-22
公司热点｜复星医药向艾力斯索赔2.55亿元：昔日合作伙伴各执一词 “药物推广”纠纷升级
曾经的合作伙伴生嫌隙，复星医药向艾力斯索赔2.55亿元
新京报网 · 10-22
曾经的合作伙伴生嫌隙，复星医药向艾力斯索赔2.55亿元
科技打头阵，如何低门槛布局科创板？
博时基金 · 10-22
科技打头阵，如何低门槛布局科创板？
加载更多
公司概况
公司名称：
上海艾力斯医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2020-12-02
主营业务：
上海艾力斯医药科技股份有限公司是一家专注于肿瘤治疗领域的创新药企业，主要产品包括艾氟替尼(第三代EGFR-TKI)、阿利沙坦酯等。目前，已在非小细胞肺癌小分子靶向药领域构建了丰富的研发管线。公司自主研发成功并对外转让的已上市产品为阿利沙坦酯片，关于阿利沙坦酯《抗高血压化学1.1类创新药物——艾力沙坦的III期临床研究》课题获得国家“重大新药创制”科技重大专项，其临床研究入选国家高技术研究发展计划（863计划）。
发行价格：
22.73
{"stockData":{"symbol":"688578","market":"SH","secType":"STK","nameCN":"艾力斯","latestPrice":53,"timestamp":1730703600000,"preClose":51.6,"halted":0,"volume":5253901,"delay":0,"floatShares":450000000,"shares":450000000,"eps":2.8816,"marketStatus":"已收盘","marketStatusCode":5,"change":1.4,"latestTime":"11-04 15:00:00","open":51.77,"high":53.35,"low":51.77,"amount":277000000,"amplitude":0.0306,"askPrice":53.01,"askSize":6,"bidPrice":53,"bidSize":87,"shortable":0,"etf":0,"ttmEps":2.8816,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1730770200000},"adr":0,"adjPreClose":51.6,"symbolType":"stock_kcb","openAndCloseTimeList":[[1730683800000,1730691000000],[1730696400000,1730703600000]],"highLimit":56.76,"lowLimit":46.44,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"pbRate":4.9,"roa":"--","roe":"23.95%","epsLYR":1.43,"committee":0.551724,"marketValue":23850000000,"floatMarketCap":23850000000,"peRate":18.39256,"changeRate":0.0271,"turnoverRate":0.0117,"status":0,"afterMarket":{"amount":0,"volume":0,"close":53,"buyVolume":0,"sellVolume":0,"time":1730705639464,"indexStatus":"已收盘 11-04 15:30:00","preClose":51.6}},"requestUrl":"/m/hq/s/688578","defaultTab":"news","newsList":[{"id":"2480001200","title":"艾力斯Q3收入增速放缓，核心产品增量市场遭竞品冲击","url":"https://stock-news.laohu8.com/highlight/detail?id=2480001200","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480001200?lang=zh_cn&edition=full","pubTime":"2024-11-01 19:30","pubTimestamp":1730460605,"startTime":"0","endTime":"0","summary":"10月24日晚发布的三季报显示，前三季度艾力斯营收同比增长87.97%，净利润同比增长158.99%，但市场对此似乎并不买单，次日开盘艾力斯股价迅速下行，最多跌超5%，最终收跌3.21%。三季报发布后，艾力斯股价已累计下跌约10%。单季度业绩增速持续放缓，或告别高速增长期同花顺iFinD显示，今年第一、二、三季度，艾力斯营收同比增速分别为168.65%、76.56%、59.73%；归母净利润同比增速分别为777.51%、101.73%、101.38%，业绩增速放缓迹象显著。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101193032a208a3ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101193032a208a3ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2480074377","title":"中原证券：给予艾力斯买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480074377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480074377?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:05","pubTimestamp":1730451932,"startTime":"0","endTime":"0","summary":"中原证券股份有限公司近期对艾力斯进行研究并发布了研究报告《季报点评：“内生+外延”双轮驱动业绩增长》，本报告对艾力斯给出买入评级，当前股价为51.6元。目前伏美替尼海外临床研究进展顺利，待其海外获批上市销售后，预计未来也将给艾力斯带来不错的收益。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100031364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","601375"],"gpt_icon":0},{"id":"2480079734","title":"阿斯利康骗保案余波未了：中国区“一把手”王磊配合调查 重磅肺癌药面临国产药“围剿”","url":"https://stock-news.laohu8.com/highlight/detail?id=2480079734","media":"ÿվ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480079734?lang=zh_cn&edition=full","pubTime":"2024-11-01 16:47","pubTimestamp":1730450844,"startTime":"0","endTime":"0","summary":"持续3年多的阿斯利康骗保案调查，在近日达到高潮。继多位公司前高管、大区经理、总监等相继接受调查后，阿斯利康全球官网在10月30日晚发布消息称，公司全球执行副总裁、国际业务主席及中国 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20241101/c663078114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688578","BK0239","BK0060","300558","688217"],"gpt_icon":0},{"id":"2480757580","title":"中原证券给予艾力斯买入评级，季报点评：“内生+外延”双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2480757580","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480757580?lang=zh_cn&edition=full","pubTime":"2024-11-01 15:54","pubTimestamp":1730447655,"startTime":"0","endTime":"0","summary":"中原证券11月01日发布研报称，给予艾力斯（688578.SH，最新价：51.6元）买入评级。评级理由主要包括：1）业绩高速增长得益于伏美替尼销售的持续放量；2）伏美替尼适应症拓展仍在稳步推进；3）在管线布局上，公司坚持“自主研发与BD引进”的“内生+外延”双轮驱动策略。风险提示：商业化不及预期风险，临床研发进度不及预期风险，海外监管政策变化风险等。AI点评：艾力斯近一个月获得1份券商研报关注，买入1家。文章来源：每日经济新闻原标题：中原证券给予艾力斯买入评级，季报点评：“内生+外延”双轮驱动业绩增长","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101160953a20779d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101160953a20779d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688578","601375"],"gpt_icon":0},{"id":"2480073194","title":"艾力斯11月01日遭主力抛售1425万元 环比增加193.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480073194","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480073194?lang=zh_cn&edition=full","pubTime":"2024-11-01 15:19","pubTimestamp":1730445569,"startTime":"0","endTime":"0","summary":"11月01日, 艾力斯股价跌0.71%，报收51.60元，成交金额2.94亿元，换手率1.25%，振幅4.23%，量比0.78。艾力斯今日主力资金净流出1425万元，连续3日净流出，上一交易日主力净流出485万元，今日环比增加193.81%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为47.37%，平均跌幅为2.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101155638a2076244&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101155638a2076244&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2479712298","title":"【机构调研记录】蜂巢基金调研特宝生物、艾力斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2479712298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479712298?lang=zh_cn&edition=full","pubTime":"2024-10-30 08:06","pubTimestamp":1730246788,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为蜂巢恒利债券A，最新单位净值为1.12，近一年增长8.73%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000009138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","688278","BK0239"],"gpt_icon":0},{"id":"2479429825","title":"【机构调研记录】英大基金调研艾力斯、华测检测","url":"https://stock-news.laohu8.com/highlight/detail?id=2479429825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479429825?lang=zh_cn&edition=full","pubTime":"2024-10-30 08:06","pubTimestamp":1730246786,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为英大中证ESG120策略指数C，最新单位净值为1.01，近一年增长11.9%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000009137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU2460026573.USD","BK0132","LU1820825898.SGD","BK0221","300012","688578","LU1146622755.USD","BK0159"],"gpt_icon":0},{"id":"2479759298","title":"【机构调研记录】汇安基金调研苑东生物、艾力斯等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2479759298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479759298?lang=zh_cn&edition=full","pubTime":"2024-10-30 08:05","pubTimestamp":1730246749,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月29日披露的机构调研信息，汇安基金近期对3家上市公司进行了调研，相关名单如下：1）苑东生物 （汇安基金参与公司特定对象调研）个股亮点：公司已成功实现20个化学药制剂产品和14个化学原料药产品的产业化，均为仿制药2）艾力斯 （汇安基金参与公司投资者电话交流会）个股亮点：公司主营为肿瘤治疗领域的创新药研发、生产及销售3）恺英网络 （汇安基金管理有限责任公司参与公司","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000009107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239","688578"],"gpt_icon":0},{"id":"2479607476","title":"10月29日艾力斯发布公告，其股东减持450万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2479607476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479607476?lang=zh_cn&edition=full","pubTime":"2024-10-29 18:00","pubTimestamp":1730196055,"startTime":"0","endTime":"0","summary":"证券之星消息，10月29日艾力斯发布公告《艾力斯:上海艾力斯医药科技股份有限公司关于公司股东减持股份结果暨权益变动达1%的提示性公告》，其股东上海艾祥企业发展中心(有限合伙)、上海艾耘企业发展中心(有限合伙)于2024年9月30日至2024年10月29日间合计减持450.0万股，占公司目前总股本的1.0%，变动期间该股股价上涨9.92%，截止10月29日收盘报53.86元。股东增减持详情见下表：根据艾力斯2024年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900034267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2479473049","title":"艾力斯10月29日现7笔大宗交易 成交金额4345.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479473049","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479473049?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:40","pubTimestamp":1730194800,"startTime":"0","endTime":"0","summary":" 10月29日，艾力斯收跌1.79%，收盘价为53.86元，发生7笔大宗交易，合计成交量86.9万股，成交金额4345.01万元。 第4笔成交价格为50.00元，成交10.60万股，成交金额529.81万元，溢价率为-7.17%，买方营业部为国泰君安证券股份有限公司广州东风中路证券营业部，卖方营业部为中信证券股份有限公司上海分公司。 进一步统计，近3个月内该股累计发生52笔大宗交易，合计成交金额为2.64亿元。该股近5个交易日累计下跌3.65%，主力资金合计净流入4602.15万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-10-29/doc-incufkfz4494383.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-10-29/doc-incufkfz4494383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2479247363","title":"10月29日艾力斯现7笔大宗交易 机构净买入750万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479247363","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479247363?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:34","pubTimestamp":1730194457,"startTime":"0","endTime":"0","summary":"证券之星消息，10月29日艾力斯发生大宗交易，交易数据如下：近三个月该股共发生52笔大宗交易，合计成交5.36万手，折价成交52笔。该股近期无解禁股上市。截至2024年10月29日收盘，艾力斯(688578)报收于53.86元，下跌1.79%，换手率1.65%，成交量7.42万手，成交额4.06亿元。该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900032295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2478139943","title":"艾力斯：伏美替尼持续快速放量、对外合作储备未来管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2478139943","media":"招商证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478139943?lang=zh_cn&edition=full","pubTime":"2024-10-27 00:00","pubTimestamp":1729958400,"startTime":"0","endTime":"0","summary":"收入增长由伏美替尼持续放量驱动，降本增效销售费用控制良好。报告期内，由于公司核心产品伏美替尼一线治疗适应症和二线治疗适应症均被续约纳入国家医保报销范围，有效降低患者的用药负担，进一步扩大了国内肺癌患者的受益群体数量，驱动业绩快速增长。研发项目推进顺利，对外合作储备未来管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102714512295bd6683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102714512295bd6683&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2478994337","title":"艾力斯（688578）10月25日主力资金净卖出39.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478994337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478994337?lang=zh_cn&edition=full","pubTime":"2024-10-26 08:18","pubTimestamp":1729901925,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月25日收盘，艾力斯报收于55.52元，下跌3.21%，换手率2.25%，成交量10.14万手，成交额5.65亿元。近5日资金流向一览见下表：艾力斯融资融券信息显示，融资方面，当日融资买入6796.8万元，融资偿还4838.15万元，融资净买入1958.65万元，连续3日净买入累计3180.49万元。艾力斯主营业务：专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102600006814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2478998628","title":"艾力斯（688578）2024年三季报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2478998628","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478998628?lang=zh_cn&edition=full","pubTime":"2024-10-26 06:08","pubTimestamp":1729894124,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期艾力斯发布2024年三季报。截至本报告期末，公司营业总收入25.33亿元，同比上升87.97%，归母净利润10.63亿元，同比上升158.99%。本报告期艾力斯应收账款上升，应收账款同比增幅达403.01%。归属于上市公司股东的扣除非经常性损益的净利润变动幅度为165.98%,原因:在营业收入增长的同时，公司推出各项降本增效措施，有效控制各项费用支出。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102600004401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578"],"gpt_icon":0},{"id":"2478290674","title":"艾力斯10月25日主力资金流入332万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2478290674","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478290674?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:19","pubTimestamp":1729840792,"startTime":"0","endTime":"0","summary":"10月25日, 艾力斯股价跌3.21%，报收55.52元，成交金额5.65亿元，换手率2.25%，振幅9.52%，量比1.50。艾力斯今日主力资金净流入332万元，连续3日净流入，上一交易日主力净流入3546万元，今日环比减少90.64%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为42.86%，平均涨幅为2.88%。该股近5个交易日上涨1.17%，主力资金累计净流入5586万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出2.39亿元，其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025154115a1e954b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025154115a1e954b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2478648223","title":"艾力斯大跌5.02% 2家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2478648223","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478648223?lang=zh_cn&edition=full","pubTime":"2024-10-25 09:39","pubTimestamp":1729820359,"startTime":"0","endTime":"0","summary":"10月25日，艾力斯股价大幅下跌，截至09点39分，艾力斯下跌5.02%，报54.48元/股，成交1.53亿元，换手率0.60%，振幅8.68%。此外，数据统计显示，近半年内2家券商给予增持建议，5家券商给予买入建议。资金动向截止发稿，艾力斯获得主力净流出707万元，其中超大单流出937万元，大单流入230万元。最新财报显示，今年三季报，艾力斯实现营业收入25.33亿元，同比增长87.97%，净利润为10.63亿元，同比增长158.99%，基本每股收益为2.36元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025094154a1e86634&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025094154a1e86634&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2477097315","title":"艾力斯(688578.SH)发前三季业绩，净利润10.63亿元，同比增长158.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477097315","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477097315?lang=zh_cn&edition=full","pubTime":"2024-10-24 17:34","pubTimestamp":1729762464,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾力斯(688578.SH)发布2024年前三季度报告，报告期内公司实现营业收入25.33亿元，同比增长87.97%;归属于上市公司股东的净利润10.63亿元，同比增长158.99%;归属于上市公司股东扣除非经常性损益净利润10.11亿元，同比增长165.98%;基本每股收益2.36元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1198901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688578"],"gpt_icon":0},{"id":"2477872738","title":"公司热点｜复星医药向艾力斯索赔2.55亿元：昔日合作伙伴各执一词 “药物推广”纠纷升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2477872738","media":"读创财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477872738?lang=zh_cn&edition=full","pubTime":"2024-10-22 14:20","pubTimestamp":1729578000,"startTime":"0","endTime":"0","summary":"今年7月9日晚间，艾力斯公告称，已收到仲裁通知，申请人江苏复星医药销售有限公司因“独家推广协议”等协议项下的合同纠纷提起仲裁。申请人请求公司支付推广服务费、律师费以及返还保证金共2929.06万元，同时要求赔偿损失2.26亿元，总额为2.55亿元。值得一提的是，对于合作纠纷，复星医药与艾力斯各执一词。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410221423159f559c74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410221423159f559c74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","688578","BK0188","BK0012","BK0175","BK0187","BK0239","BK0183","BK0096","BK0060","600196","BK0196"],"gpt_icon":0},{"id":"2477298888","title":"曾经的合作伙伴生嫌隙，复星医药向艾力斯索赔2.55亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477298888","media":"新京报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477298888?lang=zh_cn&edition=full","pubTime":"2024-10-22 10:05","pubTimestamp":1729562700,"startTime":"0","endTime":"0","summary":"复星医药子公司江苏复星医药销售有限公司与艾力斯关于肺癌药甲磺酸伏美替尼片的合作出现纠纷后，江苏复星提起仲裁申请，请求裁决艾力斯支付约2.55亿元。近日，有自媒体报道称复星医药未对上述事件进行披露。复星医药公告回应称，艾力斯系主动毁约，且此事未构成应当披露的重大事项。合作仅一年多，艾力斯就单方提出解约。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022100544ab6bfb2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022100544ab6bfb2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","02196","BK1593","688578"],"gpt_icon":0},{"id":"2477841980","title":"科技打头阵，如何低门槛布局科创板？","url":"https://stock-news.laohu8.com/highlight/detail?id=2477841980","media":"博时基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477841980?lang=zh_cn&edition=full","pubTime":"2024-10-22 07:55","pubTimestamp":1729554913,"startTime":"0","endTime":"0","summary":"多家A股半导体行业上市公司披露了2024年前三季度业绩预告，业绩普遍预喜。科创100指数ETF只需要开通上海证券交易所基金账户，且满足交易风险评级要求，即可参与交易。ETF基金的过往业绩及其净值高低并不预示其未来业绩表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688326","688568","688779","688016","688005","688582","688690","688433","688208","688439","688192","688048","688343","000698","688520","688322","688248","688739","688083","688549","688327","688702","688029","688390","688161","688153","688063","688336","688050","688432","688347","688639","688366","688037","688198","688139","688007","159982","688352","688289","688276","688266","688172","688798","688686","688097","688110","688278","688333","688484","688002","688578","688567","688608","688177","688235","688348","688612","688019","688408","688166","688700","688141","688361","688536","688498","688409","688106","688062","688318","688088","688281","688232","688425","688575","688443","688516","688146","688213","688400","688027","688548","688387","688778","688617","688001","588030","688200","688055","688052","688107","688147","688017","688066","688105","688526","688032","688789","688772","688331","688006","688556","688717","688100"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-12-02","address":"上海市浦东新区周浦镇凌霄花路268号","stockEarnings":[{"period":"1week","weight":-0.0336},{"period":"1month","weight":-0.0395},{"period":"3month","weight":0.0394},{"period":"6month","weight":-0.1697},{"period":"1year","weight":0.4619},{"period":"ytd","weight":0.2879}],"companyName":"上海艾力斯医药科技股份有限公司","boardCode":"AI0027","perCapita":"33200股","boardName":"医药制造业","registeredCapital":"45000万元","compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0079},{"period":"3month","weight":0.1545},{"period":"6month","weight":0.0581},{"period":"1year","weight":0.0922},{"period":"ytd","weight":0.1127}],"survey":" 上海艾力斯医药科技股份有限公司是一家专注于肿瘤治疗领域的创新药企业，主要产品包括艾氟替尼(第三代EGFR-TKI)、阿利沙坦酯等。目前，已在非小细胞肺癌小分子靶向药领域构建了丰富的研发管线。公司自主研发成功并对外转让的已上市产品为阿利沙坦酯片，关于阿利沙坦酯《抗高血压化学1.1类创新药物——艾力沙坦的III期临床研究》课题获得国家“重大新药创制”科技重大专项，其临床研究入选国家高技术研究发展计划（863计划）。","serverTime":1730752139806,"listedPrice":22.73,"stockholders":"13554人(较上一季度增加0.93%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾力斯,688578,艾力斯股票,艾力斯股票老虎,艾力斯股票老虎国际,艾力斯行情,艾力斯股票行情,艾力斯股价,艾力斯股市,艾力斯股票价格,艾力斯股票交易,艾力斯股票购买,艾力斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}